Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Revised International Pediatric Non-Hodgkin Lymphoma Staging System

Expert panel publishes evidence-based system

An international multidisciplinary expert panel recently published a new staging system for pediatric non-Hodgkin lymphoma. The proposed system characterizes 4 stages:

Stage

Definition

I

A single tumor, excluding mediastinum and abdomen

II

A single, extranodal tumor with regional node involvement, 2 or more nodal areas on the same side of the diaphragm, or a completely resectable primary gastrointestinal tract tumor, with or without associated mesenteric node involvement

III

2 or more extranodal tumors above and/or below the diaphragm, 2 or more nodal areas above and below the diaphragm, intra-abdominal and retroperitoneal disease, including liver, spleen, kidney, and /or ovary localizations, regardless of degree of resection, with or without involving associated mesenteric nodes that are completely resectable, any paraspinal or epidural tumor, and a single bone lesion with concomitant involvement of extranodal or nonregional nodal sites

IV

Any of the stage I to III characteristics with initial involvement of the central nervous system, bone marrow, or both

Citation: Rosolen A, Perkins SL, Pinkerton CR, et al. Revised international pediatric non-Hodgkin lymphoma staging system. [published online ahead of print May 4, 2015]. J Clin Oncol. doi:10.1200/JCO.2014.59.7203.

This Week's Must Reads

Vanderbilt staging best for predicting overall survival in retroperitoneal sarcoma, Huggett B & Cates J. Modern Pathology; 5 Nov. 2018. https://www.nature.com/articles/s41379-018-0166-8

Older patients with ccRCC may respond better to treatment than younger patients, Feulner et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.11.006.

Still no validated biomarkers to select RCC treatment, D’Avella C et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.10.027

DSS of ccRCC patients lower with high hTERT, Zanjani LS et al. Pathology. 2018 Nov 19. doi: 10.1016/j.pathol.2018.08.019.

ccRCC with papillary features best classified as a rare morphologic variant of ccRCC, Alaghehbandan R et al. Ann Diagn Pathol. 2018 Nov 22. doi: 10.1016/j.anndiagpath.2018.11.004.

Must Reads in Lymphoma & Plasma Cell Disorders

Cardiac assessment before doxorubicin treatment , Enns DL et al. Mayo Clin Proc Innov Qual Outcomes. 2018 Aug 3;2(3):277-85

Long-term data on chemo-free approach in advanced indolent lymphoma, Lockmer S et al. J Clin Oncol. 2018 Oct 4:JCO1800262. doi: 10.1200/JCO.18.00262

Race and pruritus create cancer risk picture, Kwatra SG et al. J Am Acad Dermatol. 2018 Sep 11. doi: 10.1016/j.jaad.2018.08.044.

Adding Bv improved survival for some Hodgkin patients, Evens AM et al. J Clin Oncol. 2018 Sep 4. doi: 10.1200/JCO.2018.79.0139.

First-line chemo-free MCL combo is durable, Ruan J et al. Blood. 2018 Sep 4. doi: 10.1182/blood-2018-07-859769.